We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRM:NYSESalesforce, Inc. Analysis

Data as of 2026-03-09 - not real-time

$198.79

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Salesforce (CRM) is trading at $198.79, roughly 50% below its DCF fair value of $394.89, implying a near 39% upside potential. The company delivered a Q4 revenue of $11.2 billion, beating consensus and posting a 12.1% YoY growth, while maintaining a robust 77.7% gross margin and 19.2% operating margin. Earnings per share surged to $7.80 trailing and are projected to climb to $14.91 forward, reflecting strong profitability momentum. Technical indicators show a bearish price trend with the 20‑day SMA at $191.21 below the 50‑day SMA of $218.21, yet the MACD histogram is positive (+3.35) indicating short‑term bullish pressure. Volatility remains elevated at 45.9% over 30 days, and the stock is near its resistance of $204.42, suggesting caution on immediate upside. Recent news highlights the AI‑focused Agentforce division generating $800 million in ARR and a new partnership with Formula 1 to scale fan engagement, underscoring long‑term growth catalysts. Analysts remain optimistic, with a consensus “Buy” rating and a median price target of $265, reinforcing the undervaluation thesis. The dividend yield of 0.87% is supported by a low 21% payout ratio and strong free cash flow of $16.37 billion, indicating sustainability. Overall, the blend of attractive valuation, solid fundamentals, and emerging AI revenue streams positions CRM for multi‑period upside, while short‑term price dynamics remain constrained by technical weakness and heightened volatility.
Investors should consider a cautious stance in the near term, but the medium‑ to long‑term outlook is decidedly positive, driven by AI expansion, consistent cash generation, and a defensible market position in the cloud‑software arena.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish technical trend with price below 50‑day SMA
  • Proximity to resistance level at $204.42
  • Elevated 30‑day volatility (~46%)

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervaluation vs DCF fair value and 39% upside
  • Strong AI revenue growth ($800 M ARR) and new F1 partnership
  • Analyst consensus “Buy” with median target $265

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend supported by low payout ratio and robust free cash flow
  • Long‑term AI and cloud platform tailwinds
  • Solid balance sheet with ample cash and manageable debt

Key Metrics & Analysis

Financial Health

Revenue Growth12.10%
Profit Margin17.96%
P/E Ratio25.5
ROE12.40%
ROA5.18%
Debt/Equity29.95
P/B Ratio3.1
Op. Cash Flow$15.0B
Free Cash Flow$16.4B
Industry P/E36.9

Technical Analysis

TrendBearish
RSI48.6
Support$174.57
Resistance$204.42
MA 20$191.21
MA 50$218.21
MA 200$244.40
MACDBullish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$394.89
Target Price$275.98
Upside/Downside38.83%
GradeUndervalued
TypeGrowth
Dividend Yield0.87%

Risk Assessment

Beta1.00
Volatility45.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.